Hosted on MSN5mon
Trial shows timing matters when adding immunotherapy to chemoradiation for limited-stage small cell lung cancer
Earlier this year, the landmark phase III ADRIATIC trial found adding a similar immunotherapy agent (durvalumab ... chemoradiation with or without atezolizumab immunotherapy.
Cancer Research UK1mon
Targeted and immunotherapy drugs for neuroendocrine cancer
You might have immunotherapy to treat lung neuroendocrine carcinoma (NEC). These drugs include atezolizumab and durvalumab When you might have targeted or immunotherapy drugs for neuroendocrine cancer ...
Cancer Therapy Advisor1d
ICIs Outperform Chemo for MSI-H mCRC in First Line but Not in Later Lines
Patients with MSI-H mCRC had a higher probability of survival with first-line ICI therapy than with chemotherapy, but second-line or later ICIs did not confer the same benefit.
The American Journal of Managed Care6d
Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC
Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...
The American Journal of Managed Care14d
Atezolizumab, Immunogenic Chemotherapy Combination Shows Promise for DLBCL Treatment
Othman T, Frankel P, Allen P, et al. Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica . 2025;110(1):142 ...
Hosted on MSN11mon
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
AstraZeneca Plc (NASDAQ:AZN) released updated exploratory results from the TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in combination with standard-of-care chemotherapy for advanced biliary ...